Compass Therapeutics, Inc.
Compass Therapeutics, Inc. (CMPX): 6 pipeline candidates · 2 upcoming catalysts · ~33 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
32.7 months
D/E 0.10 · 0% dilution
Lead: Phase 3
6 candidates
2 upcoming, next in ~166d
N/A
A transparent, data-derived signal for Compass Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$367.4M
Cash
$55.7M
Quarterly Burn
$17.3M
Runway
32.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
202
Total value held
$918.3M
| Holder | Shares | Value |
|---|---|---|
| tang capital management llc | 16,790,809 | $88.8M |
| orbimed advisors llc | 15,219,994 | $80.5M |
| suvretta capital management, llc | 14,307,379 | $75.7M |
| vanguard capital management llc | 12,074,350 | $63.9M |
| blackrock, inc. | 9,506,080 | $50.3M |
| adage capital partners gp, l.l.c. | 8,486,500 | $44.9M |
| enavate sciences gp, llc | 7,788,150 | $41.2M |
| bvf inc/il | 7,764,842 | $41.1M |
| state street corp | 6,694,976 | $35.4M |
| rtw investments, lp | 4,186,599 | $22.1M |
Showing top 10 of 202 institutional holders of Compass Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Compass Therapeutics, Inc.'s pipeline?
Compass Therapeutics, Inc. (CMPX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Compass Therapeutics, Inc.'s lead drug candidate?
Compass Therapeutics, Inc.'s most advanced tracked candidate is CTX-009 (Phase 2) for Metastatic Colorectal Cancer.
What is Compass Therapeutics, Inc.'s next catalyst?
Compass Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel" — expected December 1, 2026.
What is Compass Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Compass Therapeutics, Inc. has approximately 32.7 months of cash runway.
What is Compass Therapeutics, Inc.'s market capitalization?
Compass Therapeutics, Inc.'s market capitalization is approximately $367.4M.
Get the full picture on Compass Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.